J Renal Inj Prev. 2017;6(1): 18-25. doi: 10.15171/jrip.2017.04
PMID: 28487867        PMCID: PMC5414514

Case Report

Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy

Wisit Cheungpasitporn 1, Stephen L. Kopecky 2, Ulrich Specks 3, Kharmen Bharucha 1, Fernando C. Fervenza 1

Cited by CrossRef: 28

1- Fijolek J, Radzikowska E. Eosinophilic granulomatosis with polyangiitis – Advances in pathogenesis, diagnosis, and treatment. Front Med. 2023;10 [Crossref]
2- Takahashi T, Okamoto T, Sato Y, Yamazaki T, Hayashi A, Aoyagi H, Ueno M, Kobayashi N, Uetake K, Nakanishi M, Ariga T. Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study. Pediatr Nephrol. 2019;34(1):87 [Crossref]
3- Bond M, Fagni F, Moretti M, Bello F, Egan A, Vaglio A, Emmi G, Dejaco C. At the Heart of Eosinophilic Granulomatosis with Polyangiitis: into Cardiac and Vascular Involvement. Curr Rheumatol Rep. 2022;24(11):337 [Crossref]
4- Desai A, Noor A, Joshi S, Kim A. Takotsubo cardiomyopathy in cancer patients. Cardio-Oncology. 2019;5(1) [Crossref]
5- Şener Y. Chemotherapy and atrial fibrillation. Asia-Pac J Clncl Oncology. 2020;16(6):400 [Crossref]
6- Lu W, Gong S, Li J, Luo H, Wang Y. Efficacy and safety of rituximab in the treatment of membranous nephropathy. 2020;99(16):e19804 [Crossref]
7- Gumerova K, Sakhautdinova G, Polyakova I. Antitumour Drug Induced Cardiovascular Toxicity and Current Tumour Treatment Methods. Kreativnaâ hirurgiâ i onkologiâ. 2020;9(4):285 [Crossref]
8- Varghese R, Majumdar A. Current Therapies in Nephrotic Syndrome: HDAC inhibitors, an Emerging Therapy for Kidney Diseases. Current Research in Biotechnology. 2021;3:182 [Crossref]
9- Gupta R, Sen A, Khosla J, Ranchal P, Aronow W, Shehu M. Takotsubo Cardiomyopathy Secondary to Rituximab. 2022;29(4):451 [Crossref]
10- Cole C, Amber K. Off-Label Uses of Rituximab in Dermatology. Curr Derm Rep. 2022;11(4):209 [Crossref]
11- Nieto-Gañán I, Iturrieta-Zuazo I, Rita C, Carrasco-Sayalero Á. Revisiting immunological and clinical aspects of membranous nephropathy. Clinical Immunology. 2022;237:108976 [Crossref]
12- Ko Ko N, Minaskeian N, El Masry H. A case of irreversible bradycardia after rituximab therapy for diffuse large B-cell lymphoma. Cardio-Oncology. 2020;6(1) [Crossref]
13- Bayer G, Agier M, Lioger B, Lepelley M, Zenut M, Lanoue M, Maillot F, Jonville-Bera A. Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: A French nationwide study. European Journal of Internal Medicine. 2019;67:59 [Crossref]
14- Patil V, Lunge S, Doshi B. Cardiac side effect of rituximab. Indian J Drugs Dermatol. 2020;6(1):49 [Crossref]
15- Raimondi L, Raimondi F, Rossi L, Lazzeroni R, Pietranera M, Di Benedetto L, Gozzi E, Spinelli G. Gemcitabine-induced dilated-cardiomyopathy in patient with platinum-refractory ovarian-cancer: A case report and literature review. J Oncol Pharm Pract. 2021;27(6):1542 [Crossref]
16- Sener S, Arslanoglu Aydin E, Batu E. Cardiac involvement and cardiovascular risk factors in pediatric primary systemic vasculitides. Clin Rheumatol. 2023;42(3):673 [Crossref]
17- Al-Yafeai Z, Carvajal-González A, Abduljabar H, Arvas M, Patel S, Patel N. Novel multiple sclerosis agents-associated cardiotoxicity: A real-world pharmacovigilance study. International Journal of Cardiology. 2022;362:153 [Crossref]
18- Monti M, Cortesi P, Vespignani R, Bronico I, Gallio C, Flospergher M, Matteucci L, Frassineti G. Takotsubo Syndrome (TTS) in Onco-Hematologic Patients: Retrospective Analysis and Focus on the Correlation or Not With Anticancer Drugs. Case Reports and Review of the Literature. Front Oncol. 2022;12 [Crossref]
19- Farkas A, Marcott M, Yanta J, Pizon A. Bicarbonate refractory QRS prolongation and left bundle‐branch block following escitalopram and lamotrigine overdose: A case report and literature review of toxic left bundle‐branch block. J Clin Pharm Ther. 2018;43(5):717 [Crossref]
20- Girkar N, Zaki S, Pawar S, Dhande P. Reversible Cardiomyopathy after Rituximab Treatment in a Chronic Lymphocytic Leukemia Patient. J Oncol Pharm Pract. 2022;28(7):1650 [Crossref]
21- Pozdzik A, Brochériou I, David C, Touzani F, Goujon J, Wissing K. Membranous Nephropathy and Anti-Podocytes Antibodies: Implications for the Diagnostic Workup and Disease Management. BioMed Research International. 2018;2018:1 [Crossref]
22- Tamargo J, Caballero R, Delpón E. Cancer Chemotherapy-Induced Sinus Bradycardia: A Narrative Review of a Forgotten Adverse Effect of Cardiotoxicity. Drug Saf. 2022;45(2):101 [Crossref]
23- Rihackova E, Rihacek M, Vyskocilova M, Valik D, Elbl L. Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma—a review and prospects for the future. Front Cardiovasc Med. 2023;10 [Crossref]
24- Mishra N, Sharma A, Shalini S, Sharma S, Jain P, Sharma R, Chander H, Prasad J, Anvikar A, Chand S. National Control Laboratory Assessment of Quality of Rituximab Biosimilars in India. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. 2022;41(5):260 [Crossref]
25- Sadia A, Yasmin T, Imran M, Samra M, Raza Basra M. Calcium complexes of oxicams: new dimensions in rheumatoid arthritis treatment. Future Medicinal Chemistry. 2022;14(23):1771 [Crossref]
26- Deng L, Xu G. Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy. Drugs. 2023;83(6):507 [Crossref]
27- Perpinia A, Kadoglou N, Vardaka M, Gkortzolidis G, Karavidas A, Marinakis T, Papachrysostomou C, Makaronis P, Vlachou C, Mantzourani M, Farmakis D, Konstantopoulos K. Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies. Pharmaceuticals. 2022;15(8):1007 [Crossref]
28- Aimo A, Tavoni A, Buda G, Emdin M, Dinov B, Asher E, Musella F, Tan T. Rituximab as a novel treatment for heart failure: evidence from a case series. 2019;3(4):1 [Crossref]